Postdoctoral Research Fellow, Shiva Malek, Genentech Research

Job description

  Job facts
We have an opening for a talented Post-doctoral Fellow to join the laboratory of Dr. Shiva Malek in the Discovery Oncology Department at Genentech. The focus of the lab is to use structural, biochemical and cellular approaches to study MAPK signaling in RAS mutant tumors. Given our interest in small molecule inhibitors of this pathway, we routinely use chemical biology approaches to dissect mechanisms of regulation and signaling in this pathway as well. The successful candidate will have experience in protein purification, protein characterization, enzymology and characterization of protein-protein interactions as well as experience in cellular experiments (tissue culture, IP western and mass spec, signaling experiments, siRNA/CRISPR, generation of stable cell lines, various growth assays) using mammalian tumor cells. While experience in solving crystal structures of proteins is not required, familiarity with Pymol or other similar software is preferred for evaluating protein structures in order to develop structure-based hypothesis to test in biochemical and cellular experiments. The lab projects are focused on building mechanistic hypotheses using biochemical experiments/approaches and testing those hypotheses in relevant cellular models. Experience with kinase or pseudokinase proteins is a plus as is any experience with biophysical methods including mass spectrometry, high-content microscopy, and/or fluorescence based approaches to study protein-protein interactions biochemically and in cells. The lab has access to state of the art mass spectrometry facilities, a structural biology group, automation for high-throughput screening, access to libraries of small molecule compounds as well as access to in vivo mouse model development.

Relevant Lab Publications:

Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, Yu C, Shaw AS, Manning G, Skelton NJ, Hymowitz SG, Malek S*. (2016) Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell 29(4):477-93.

Haling J, Sudhamsu J, Sideris S, Yen I, Nguyen L, Sandoval W, Phung W, Bravo B, Giannetti A, Peck A, Masselot A, Morales T, Smith D, Brandhuber B, Hymowitz S*, Malek S*. (2014) Structure of the BRAF:MEK complex reveals a kinase independent role for BRAF in MAPK Signaling, Cancer Cell, 26: 402-413.

Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, Ludlam MJ, Wiesmann C, Ultsch M, Friedman LS, Malek S, Belvin M. (2013). Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 501(7466):232-6.

G. Hatzivassiliou*, K. Song, I. Yen, B. J. Brandhuber, D. J. Anderson, R. Alvarado, M. J.C. Ludlam, D. Stokoe, S. L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K. P. Hoeflich, B. S. Jaiswal1, S. Seshagiri, H/ Koeppen, M. Belvin, L. S. Friedman, S. Malek* (2010). RAF inhibitors prime wildtype RAF to activate the MAPK pathway and enhance growth. Nature, 464:431-435.

For more information about our Postdoctoral Program, please visit:
http://www.gene.com/careers/academic-programs/postdocs

For more information on Shiva Malek lab, please visit: https://www.gene.com/scientists/our-scientists/shiva-malek

·  Who we are

A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.

Roche is an equal opportunity employer and strictly prohibits unlawful discrimination based upon an individual's race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, mental/physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law.

If you have a disability and need an accommodation in connection with the on-line application process, please email us at .
EEO is the Law

PAY TRANSPARENCY NONDISCRIMINATION PROVISION
The contractor will not discharge or in any other manner discriminate against employees or applicants because they have inquired about, discussed, or disclosed their own pay or the pay of another employee or applicant. However, employees who have access to the compensation information of other employees or applicants as a part of their essential job functions cannot disclose the pay of other employees or applicants to individuals who do not otherwise have access to compensation information, unless the disclosure is (a) in response to a formal complaint or charge, (b) in furtherance of an investigation, proceeding, hearing, or action, including an investigation conducted by the employer, or (c) consistent with the contractor's legal duty to furnish information. 41 CFR 60-1.35(c)

Desired profile

Who you are

You're someone who wants to influence your own development. You're looking for a company where you have the opportunity to pursue your interests across functions and geographies. Where a job title is not considered the final definition of who you are, but the starting point.
The qualified individual will possess a Ph.D. in Biochemistry, Cell Biology or related field with a solid publication record with at least one first author publication in a high impact journal. Excellent communication and writing skills as well as a track record of working in highly collaborative environments is a must.

*LI-gRED-GL1

·